Wikipedia:Featured article review/Prostate cancer/archive1 - Wikipedia


Article Images
The following is an archived discussion of a featured article review. Please do not modify it. Further comments should be made on the article's talk page or at Wikipedia talk:Featured article review). No further edits should be made to this page.

The article was removed by YellowAssessmentMonkey 00:30, 12 May 2009 [1].

This article has a number of issues.

  • There is a lack of images.
  • The prose dose not flow very well ( "and other symptoms" "South and East Asia detecting less frequently than in Europe")
  • Lack of depth of some section ( no discussion of numerical comparison of rates of occurrence and mortality world wide in the epidemiology section )
  • Ref need a lot of work ( no PMID for 145, 146, 148, 149 and others )
  • Issues with formatting of numbers (eg almost 9 years )
  • There is an article on Prostate cancer screening but the main article still describes studies in detail. Not encyclopedic as does not summarize.
  • Does this belong in the epidemiology section? "Many factors, including genetics and diet, have been implicated in the development of prostate cancer. The Prostate Cancer Prevention Trial found that finasteride reduces the incidence of prostate cancer rate by 30%. There had been a controversy about this also increasing the risk of more aggressive cancers, but more recent research showed this was not the case.[143][45]"
The significance of this is questionable: Uptodate says:

There was a 25 percent decrease in the incidence of prostate cancer in men assigned to finasteride (803 of 4368 [18.4 percent] versus 1147 of 4692 [24.4 percent] with placebo). The magnitude of the risk reduction did not differ according to PSA level, age, race/ethnicity, or family history of prostate cancer.

Despite the overall decrease in cases of prostate cancer among those receiving finasteride, both the absolute number and proportion of more aggressive prostate cancers (ie, Gleason score ≥7) were significantly higher in the finasteride group (280 of 757 [37 percent] versus 237 of the 1068 [22 percent] in the placebo group). However, 98 percent of tumors were T1 or T2 in both groups, and only five men in each group died of prostate cancer.

Treatment was well tolerated. Finasteride increased sexual dysfunction only slightly by six months after randomization compared to placebo, and its impact diminished over time [12]. Urinary symptoms were less common in the finasteride group (frequency or urgency, 12.9 versus 15.6 percent with placebo, urinary retention, 4.2 versus 6.3 percent, need for transurethral resection of the prostate, 1.0 versus 1.9 percent) [11].

  • This article needs more than just cosmetic fixes.

--Doc James (talk · contribs · email) 13:48, 13 April 2009 (UTC)[reply]

Some use of primary sources (see WP:MEDRS), sentence fragments, short stubby sections, needs better organization to conform to WP:MEDMOS, but the article looks salvageable. If some of the doctors get involved on the medical information, I'll help with cleanup. SandyGeorgia (Talk) 14:07, 13 April 2009 (UTC)[reply]
I'll give you hand cleaning this up over the next few days. Recommend cross-posting to WT:MED if you haven't already done so. If we can get some discussing going about which sources are particularly dubious, I'll set about going through PubMed for some alternatives. --—Cyclonenim | Chat  22:11, 14 April 2009 (UTC)[reply]
Suggested FA criteria concern is citations, prose, structure, stubby sections/1-line paragraphs. Also note the recent change to WP:WIAFA (1c) requiring "high-quality" sources. YellowMonkey (cricket calendar poll!) 00:35, 29 April 2009 (UTC)[reply]
The above discussion is preserved as an archive. Please do not modify it. No further edits should be made to this page.